Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes

Journal of Clinical Oncology

Volumn 22, Issue 8, 2004, Pages 1460-1468

  Corradini, Paolo ^a   Ladetto, Marco ^a   Zallio, Francesco ^a   Astolfi, Monica ^a   Rizzo, Elena ^a   Sametti, Selina ^a   Cuttica, Alessandra ^a   Rosato, Rosalba ^a   Farina, Lucia ^a   Boccadoro, Mario ^a   Benedetti, Fabio ^a   Pileri, Alessandro ^a   Tarella, Corrado ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 1; PROTEIN BCL 2; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; FOLLICULAR LYMPHOMA; GENE REARRANGEMENT; HUMAN; IMMUNOGLOBULIN GENE; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; ADULT; AUTOTRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; LYMPHOMA, SMALL LYMPHOCYTIC; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; TRANSPLANTATION, AUTOLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 2342562484     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.054     Document Type: Article

References (57)

1. Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987
2. Gianni AM, Bregni M, Siena S, et al: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336: 1290-1297, 1997
3. Shipp MA, Abeloff MD, Antman KH, et al: International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the jury. J Clin Oncol 17:423-129, 1999
4. Freedman AS, Ritz J, Neuberg D, et al: Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 77:2524-2529, 1991
5. Horning SJ: Treatment approaches to the low-grade lymphomas. Blood 83:881-884, 1994
6. Rohatiner AZS, Johnson PWM, Price CGA, et al: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12:1177-1784, 1994
7. Stewart DA, Vose JM, Weisenburger DD, et al: The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 6:263-266, 1995
8. Takvorian T, Canellos GP, Ritz J, et al: Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 316:1499-1505, 1987
9. Haas R, Moos M, Karcher A, et al: Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 12:1685-1692, 1994
10. Bastion Y, Brice P, Haioun C, et al: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 86:3257-3262, 1995
11. Bierman PJ, Vose JM, Anderson JR, et al: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997
12. Tarella C, Caracciolo D, Corradini P, et al: Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia 14:740-747, 2000
13. Horning SJ, Negrin RS, Hoppe RT, et al: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial. Blood 97:404-409, 2001
14. Hunault-Berger M, Ifrah N, Solal-Celigny P, et al: Intensive therapies in follicular non-Hodgkin lymphomas. Blood 100:1141-1152, 2002
15. Gribben JG, Neuberg D, Freedman AS, et al: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81: 3449-3457, 1993
16. Freedman AS, Gribben JG, Neuberg D, et al: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780-2786, 1996
17. Corradini P, Astolfi M, Cherasco C, et al: Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 89:724-731, 1997
18. Ladetto M, Corradini P, Vallet S, et al: High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: A multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 100:1559-1565, 2002
19. Gribben JG, Freedman AS, Neuberg D, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325: 1525-1533, 1991
20. Hardingham JE, Kotasek D, Sage RE, et al: Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 13:1073-1079, 1995
21. Moos M, Schulz R, Martin S, et al: The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukemia 12:1971-1978, 1998
22. Freedman AS, Neuberg D, Mauch P, et al: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999
23. Apostolidis J, Gupta RK, Grenzelias D, et al: High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up. J Clin Oncol 18:527-536, 2000
24. Corradini P, Ladetto M, Pileri A, et al: Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: A critical reappraisal of molecular strategies. Leukemia 13:1691-1695, 1999
25. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 84:1361-1392, 1994
26. Lopez-Guillermo A, Montserrat E, Bosch F, et al: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12:1343-1348, 1994
27. Voena C, Ladetto M, Astolfi M, et al: A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 11:1793-1798, 1997
28. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1250, 1999
29. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-463, 1958
30. Peto R: Asymptotically efficient rank invariant test procedures. J R Stat Soc 135:185-206, 1972
31. Cox DR: Regression models and life tables. J R Stat Soc (B) 34:187-220, 1972
32. Campana S, Corradini P, Astolfi M, et al: Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. Bone Marrow Transplant 20:341-343, 1997
33. Ladetto M, Sametti S, Astolfi M, et al: Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting. Leuk Lymphoma 40:679-682, 2001
34. Fouillard L, Laporte JP, Labopin M, et al: Autologous stem-cell transplantation for non-Hodgkin's lymphomas: The role of graft purging and radiotherapy posttransplantation results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 16:2803-2816, 1998
35. Martin-Henao GA, Picon M, Limon A, et al: Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL). Bone Marrow Transplant 23:579-587, 1999
36. + autologous transplant in relapsed follicular lymphoma. Hematol Cell Ther 39:33-40, 1997
37. Mahé B, Milpied N, Mellerin MP, et al: PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 31:467-473, 2003
38. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
39. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
40. Robertson LE, Redman JR, Butler JJ, et al: Discordant bone marrow involvement in diffuse large-cell lymphoma: A distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol 9:236-242, 1991
41. Lerner RE, Burns LJ: Transformed lymphoma: An Achilles' heel of non Hodgkin's lymphoma. Bone Marrow Transplant 31:531-537, 2003
42. Yuen AR, Kamel OW, Halpern J, et al: Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 13:1726-1733, 1995
43. Bastion Y, Sebban C, Berger F, et al: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587-1594, 1997
44. Friedberg JW, Neuberg D, Gribben JG, et al: Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 5:262-268, 1999
45. Chen CI, Crump M, Tsang R, et al: Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 113:202-208, 2001
46. Williams CD, Harrison CN, Lister TA, et al: High dose therapy and autologous stem cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: A case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 19: 727-735, 2001
47. Andersen NS, Donovan JW, Borus JS, et al: Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 90:4212-4221, 1997
48. Pappa VI, Wilkes S, Salam A, et al: Use of the polymerase chain reaction and direct sequencing analysis to detect cells with the t(14;18) in autologous bone marrow from patients with follicular lymphoma, before and after in vitro treatment. Bone Marrow Transplant 22:553-558, 1998
49. Johnson PWM, Price CGA, Smith T, et al: Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 12:798-805, 1994
50. Gribben JG, Saporito L, Barber M, et al: Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood 80:1083-1089, 1992
51. Tarella C, Corradini P, Astolfi M, et al: Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: Evidence for long-term clinical and molecular remissions. Leukemia 13: 1456-1462, 1999
52. Magni M, Di Nicola M, Devizzi L, et al: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood 96: 864-869, 2000
53. Voso MT, Pantel G, Weis M, et al: In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 109: 729-735, 2000
54. Ladetto M, Zallio F, Vallet S, et al: Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotnerapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 15:1941-1949, 2001
55. Khouri IF, Saliba RM, Giralt SA, et al: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98:3595, 2001
56. Corradini P, Tarella C, Olivieri A, et al: Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99: 75-82, 2002
57. Khouri IF, Lee MS, Saliba RM, et al: Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21:4407-4412, 2003